Eton Pharmaceuticals, Inc. ETON Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.66M+12.9% | $25.94M+73.7% | $37.12M+83.2% | $25.38M+43.4% | $17.42M+4.6% | ||
| $13.41M-18.2% | $11.76M+119% | $13.08M+134% | $14.45M+197% | $16.4M+287% | ||
| $14.47M+6.2% | $15.42M+1.2% | $16.86M+770% | $23.79M+1,050% | $13.62M+488% | ||
| $5.71M+127% | $7.46M+35.9% | $4.94M+152% | $4.82M+503% | $2.52M+140% | ||
| $53.25M+6.6% | $60.58M+47.7% | $72M+142% | $68.44M+169% | $49.96M+106% | ||
| $372K+1,591% | $326K+859% | $294K+791% | $18K-60.0% | $22K-61.4% | ||
| $301K+90.5% | $310K+77.1% | $319K+65.3% | $333K+52.1% | $158K+114% | ||
| $43.74M+29.1% | $30.88M-11.5% | $31.88M+445% | $32.88M+437% | $33.88M+430% | ||
| $54K+350% | $19K+58.3% | $19K+58.3% | $12K0.0% | $12K0.0% | ||
| $97.71M+16.3% | $92.11M+21.0% | $104.51M+192% | $101.68M+220% | $84.03M+173% | ||
| $13.49M+177% | $10.98M+163% | $14.26M+431% | $12.14M+469% | $4.87M+115% | ||
| $7.75M+2.7% | $9.41M+5.5% | $9.12M+86.9% | $7.46M-34.7% | $7.54M-5.9% | ||
| $11.81M— | $8.79M— | $2.78M-32.7% | $2.77M-40.6% | —— | ||
| $75K-2.6% | $65K-14.5% | $30K-60.0% | $23K-68.9% | $77K-11.5% | ||
| $44.18M+74.3% | $38.49M+93.0% | $44.18M+124% | $38.6M+112% | $25.35M+65.7% | ||
| $18.94M-36.9% | $21.77M-27.0% | $27.59M— | $27.41M— | $29.99M— | ||
| $440K+406% | $460K+330% | $480K+281% | $492K+239% | $87K— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $515K+214% | $525K+187% | $510K+154% | $522K+138% | $164K+88.5% | ||
| $3.54M-14.8% | $5.24M+186% | $3.94M— | $4.27M— | $4.15M— | ||
| $67.1M+12.6% | $65.96M+27.6% | $81.38M+310% | $77.72M+323% | $59.58M+289% | ||
| $27K0.0% | $27K0.0% | $27K+3.8% | $27K+3.8% | $27K+3.8% | ||
| $141.53M+5.7% | $138.62M+4.8% | $137.08M+11.2% | $135.98M+12.1% | $133.89M+11.2% | ||
| -$110.94M-1.3% | -$112.49M-4.3% | -$113.98M-6.2% | -$112.05M-3.8% | -$109.47M-4.4% | ||
| $30.62M+25.2% | $26.15M+7.1% | $23.13M+44.7% | $23.96M+78.0% | $24.45M+57.8% | ||
| $97.71M+16.3% | $92.11M+21.0% | $104.51M+192% | $101.68M+220% | $84.03M+173% | ||
| $54K+350% | $19K+58.3% | $19K+58.3% | $12K0.0% | $12K0.0% | ||
| $301K+90.5% | $310K+77.1% | $319K+65.3% | $333K+52.1% | $158K+114% | ||
| $43.74M+29.1% | $30.88M-11.5% | $31.88M+445% | $32.88M+437% | $33.88M+430% | ||
| $301K+90.5% | $310K+77.1% | $319K+65.3% | $333K+52.1% | $158K+114% | ||
| $54K+350% | $19K+58.3% | $19K+58.3% | $12K0.0% | $12K0.0% | ||
| $301K+90.5% | $310K+77.1% | $319K+65.3% | $333K+52.1% | $158K+114% | ||
| $54K+350% | $19K+58.3% | $19K+58.3% | $12K0.0% | $12K0.0% | ||
| $7.75M+2.7% | $9.41M+5.5% | $9.12M— | $7.46M-34.7% | $7.54M-5.9% | ||
| $7.75M+2.7% | $9.41M+5.5% | $9.12M— | $7.46M-34.7% | $7.54M-5.9% | ||
| $31.26M+3.7% | $31.08M+3.6% | $30.88M+614% | $30.7M+529% | $30.16M+490% | ||
| $141.53M+5.7% | $138.62M+4.8% | —— | —— | $133.89M+11.2% | ||
| $27K0.0% | $27K0.0% | $27K+3.8% | $27K+3.8% | $27K+3.8% | ||
| $11.14M-13.9% | $9.32M+35.7% | $18.03M+124% | $16.23M— | $12.94M— | ||
| $11.81M— | $8.79M— | $2.78M— | $2.77M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Eton Pharmaceuticals, Inc.'s total assets?
- Eton Pharmaceuticals, Inc. (ETON) holds $97.7M in total assets, up 16.3% year over year.
- How much debt does Eton Pharmaceuticals, Inc. have?
- Eton Pharmaceuticals, Inc. carries $31.3M in total debt against $30.6M of shareholders' equity, a debt-to-equity ratio of 1.02.
- How much cash does Eton Pharmaceuticals, Inc. have?
- Eton Pharmaceuticals, Inc. holds $19.7M in cash and equivalents.
- Can Eton Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 1.21 — current assets exceed current liabilities.
- Where does Eton Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Eton Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
